Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Ahmet Emre Eşkazan, Rıdvan Ali, Ebru Alnıgeniş, Orhan Ayyıldız, İbrahim Haznedaroğlu, Onur Kırkızlar, Erdal Kurtoğlu, Simten Malhan, Ergün Öksüz, Özlem Polat, Güray Saydam, Mehmet Sönmez, Selami Koçak Toprak, Tayfur Toptaş & Mehmet Turgut. (2022) Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting. Expert Review of Hematology 15:2, pages 97-106.
Read now
Read now
Ahmet Emre Eskazan. (2019) Is measuring plasma imatinib trough levels still an appropriate way for predicting responses in patients with chronic myeloid leukemia?. Leukemia & Lymphoma 60:8, pages 2094-2095.
Read now
Read now
Ahmet Emre Eskazan. (2018) The issue of financial toxicity in the management of chronic myeloid leukemia with blast crisis. Journal of Medical Economics 21:7, pages 709-711.
Read now
Read now
Andrés Gomez-de-León, David Gómez-Almaguer, Guillermo J. Ruiz-Delgado & Guillermo J. Ruiz-Arguelles. (2017) Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective. Expert Review of Hematology 10:9, pages 809-819.
Read now
Read now
Ahmet Emre Eskazan & Teoman Soysal. (2015) The current situation and future aspects of cost-effectiveness in chronic myeloid leukemia treatment. Leukemia & Lymphoma 56:5, pages 1554-1555.
Read now
Read now
Articles from other publishers (11)
Abdülkadir Erçalışkan, Duygu Seyhan Erdoğan & Ahmet Emre Eşkazan. (2021) Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs. Blood Advances 5:17, pages 3344-3353.
Crossref
Crossref
Blanca Xicoy & Lurdes Zamora. (2020) Tratamiento actual de las neoplasias mieloproliferativas: frente a tres escenarios. Medicina Clínica 154:4, pages 131-133.
Crossref
Crossref
Blanca Xicoy & Lurdes Zamora. (2020) Current treatment of myeloproliferative neoplasias: three scenarios. Medicina Clínica (English Edition) 154:4, pages 131-133.
Crossref
Crossref
Meinolf Suttorp, Markus Metzler, Frederic Millot, Hiroyuki Shimada, Deepak Bansal, Adalet Meral Günes, Krzysztof Kalwak, Petr Sedlacek, Andre Baruchel, Andrea Biondi, Nobuko Hijiya, Kirk R. Schultz & Martin Schrappe. (2018) Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients. Pediatric Blood & Cancer 65:12, pages e27431.
Crossref
Crossref
Ahmet Emre Emre Eskazan & Mario Tiribelli. (2018) Allogeneic Haematopoietic Stem Cell Transplantation for Chronic Myeloid Leukaemia in the Era of Tyrosine Kinase Inhibitors. EMJ Hematology, pages 63-70.
Crossref
Crossref
Ahmet Emre Eşkazan. (2018) Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?. British Journal of Clinical Pharmacology 84:8, pages 1635-1638.
Crossref
Crossref
Ahmet Emre Eskazan, Sevil Sadri, Dilek Keskin, Mesut Ayer, Bulent Kantarcioglu, Naciye Demirel, Demet Aydin, Fuat Aydinli, Osman Yokus, Isil Erdogan Ozunal, Selin Berk, Fevzi Firat Yalniz, Tugrul Elverdi, Ayse Salihoglu, Muhlis Cem Ar, Seniz Ongoren, Zafer Baslar, Yildiz Aydin, Nukhet Tuzuner, Ugur Ozbek & Teoman Soysal. (2017) Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec. Clinical Lymphoma Myeloma and Leukemia 17:12, pages 804-811.
Crossref
Crossref
Ahmet Emre Eskazan & Dilek Keskin. (2017) Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update. Therapeutic Advances in Hematology 8:9, pages 237-243.
Crossref
Crossref
Erna Islamagic, Azra Hasic, Sabira Kurtovic, Emina Suljovic Hadzimesic, Lejla Mehinovic, Mirza Kozaric & Amina Kurtovic-Kozaric. (2017) The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 17:4, pages 238-240.
Crossref
Crossref
Alen Ostojic, Dubravka Sertic, Pavle Roncevic, Zinaida Peric, Paula Granic, Nikolina Matic, Sandra Basic-Kinda, Ranka Serventi-Seiwerth, Ivo Radman, Renata Zadro & Damir Nemet. (2016) Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study. Clinical Lymphoma Myeloma and Leukemia 16:8, pages 472-476.
Crossref
Crossref
Ahmet Emre Eskazan & Teoman Soysal. (2015) Generic imatinib in the treatment of chronic myeloid leukemia: Cerrahpaşa experience. Journal of Oncology Pharmacy Practice 22:2, pages 382-384.
Crossref
Crossref